Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Towns wants answers on J&J's alleged "phantom recall"

This article was originally published in The Tan Sheet

Executive Summary

Rep. Edolphus Towns investigates whether Johnson & Johnson and subsidiary McNeil Consumer Healthcare hired contractors to buy all of a small Motrin stock-keeping unit as part of a "phantom recall" in 2008. "The company's motivation was apparently to save itself the embarrassment and potential financial loss associated with a recall," said Towns, chairman of the House Oversight and Government Reform Committee. The New York Democrat June 3 sent a 1letter to contractor WIS and a separate 2letter to Inmar Inc. - whose subsidiary Carolina Supply Chain Services may have recruited WIS to purchase the affected Motrin, Towns said. The letters ask the firms for details on what J&J contracted them to do. J&J OTC executive Colleen Goggins testified May 27 she was unaware of the contractors secretly purchasing the product, which failed to meet dissolution standards and was recalled formally in 2009 (3"The Tan Sheet" May 31, 2010)

You may also be interested in...

Congress Wants More Answers From J&J On "Phantom Recall"

Johnson & Johnson's response to a congressional inquiry regarding the alleged "phantom recall" of a Motrin product left a House committee chairman considering whether to subpoena additional information

J&J Faces Possible Criminal Liability As Post-Recall Overhaul Continues

FDA's drug center referred its review of Johnson & Johnson's manufacturing operations to the Office of Criminal Investigations, which will determine whether there is criminal liability in the quality control lapses that led to extensive recalls of OTC drugs

Long-Term Data Boost Novartis And Roche SMA Challenge To Biogen’s Spinraza

New long-term data from Novartis’s Zolgensma and Roche’s Erysdi will help close the gap on Biogen’s market leader Spinraza, but the three therapies look set to develop distinct or even complementary roles as the market matures.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts